RayKnowChina Research Map
Shortlist

Southern Medical University

南方医科大学

GuangzhouUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
3.3%Leads about 1 in 30 of China's research papers on NPC

Led 79 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
6
Research papers it led
79
Trials it led
9
Share of China's trials
1.5%
Share of the world's papers
2.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesRecurrent / metastatic diseaseImaging & AIEBV & screening

Over half of these papers are lab or animal studies.

Papers it led5
  1. Aberrant lipid metabolism reshapes the immune landscape in bone metastasis of nasopharyngeal carcinoma.2025Journal for immunotherapy of cancerFree full text
  2. Development and Evaluation of an Optimal Machine Learning Model for Predicting Nutritional Risk in Nasopharyngeal Carcinoma Patients: A Cross-Sectional Study.2026Nutrition and cancer
  3. A dynamic online nomogram for predicting nutritional risk in nasopharyngeal carcinoma patients after radiotherapy.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  4. Clinical analysis of intracranial and extracranial vascular bypass surgery for carotid blowout syndrome in nasopharyngeal carcinoma.2025Neurosurgical review
  5. The impact of different cervical planning target volume designs on efficacy and toxicity in nasopharyngeal carcinoma: a single-center retrospective study.2025BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal CarcinomaRecruitingNCT07819656Lead sponsorStart 2026-08
  2. A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal MucositisRecruitingNCT06287788Lead sponsorStart 2024-03
  3. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Lead sponsorStart 2024-04
  4. Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral MucositisRecruitingNCT06307314Lead sponsorStart 2024-02
  5. Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal CarcinomaRecruitingNCT06017895Lead sponsorN/AStart 2023-10
  6. Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaRecruitingNCT03919552Lead sponsorPhase 3Start 2018-01

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.5%Leads under 1 in 100 of China's research papers on ESCC

Led 14 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
4
Research papers it led
14
Trials it led
6
Share of China's trials
1.1%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025
ThemesImmunotherapyMolecular markers & genomicsNeoadjuvant & combined treatment

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Nanfang Hospital8
  2. Zhujiang Hospital4
  3. Dongguan People's Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Fungal microbiota signatures anticipate neoadjuvant immunochemotherapy outcomes in esophageal cancer.2025Journal for immunotherapy of cancerFree full text
  2. Association Between Treatment-Related Adverse Event Trajectory and Prognosis in Esophageal Cancer Receiving Neoadjuvant Immunochemotherapy.2025Annals of surgical oncology
  3. Global burden of esophageal cancer attributable to high BMI in 204 countries and territories: 1990-2019.2024Thoracic cancerFree full text
  4. High Kin17 expression is correlated with metastasis and prognosis of esophageal squamous cell carcinoma.2025The International journal of biological markers
  5. Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer.2023Cell death & diseaseFree full text
Trials on ClinicalTrials.gov6
  1. Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)RecruitingNCT07627347Lead sponsorN/AStart 2026-05
  2. A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06843889Lead sponsorPhase 2Start 2025-04
  3. Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05214222Lead sponsorPhase 2Start 2022-09
  4. Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal AntibodyRecruitingNCT05392413Lead sponsorStart 2022-08
  5. Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06885814Lead sponsorPhase 2Start 2024-06
  6. Exploration and Verification of DNA Methylolation in Early Screening of Esophageal CancerStatus unknownNCT03922230Lead sponsorStart 2019-03

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.6%Leads about 1 in 62 of China's research papers on HCC

Led 239 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
12
Research papers it led
239
Trials it led
29
Share of China's trials
2.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection

Hospitals counted here

  1. Nanfang Hospital127
  2. Zhujiang Hospital54
  3. Shenzhen Hospital, Southern Medical University Counted in the group total12
  4. Integrated Hospital, Southern Medical University Counted in the group total8
  5. Shunde Hospital of Southern Medical University Counted in the group total7
  6. Third Affiliated Hospital of Southern Medical University Counted in the group total4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.2025Frontiers in immunologyRCTFree full text
  2. Short-term prognosis for hepatocellular carcinoma patients with lung metastasis: A retrospective cohort study based on the SEER database.2022MedicineRCTFree full text
  3. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.2023Journal of hepatology
  4. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma.2024Signal transduction and targeted therapyFree full text
  5. An individualized cirrhosis screening strategy might be more cost-effective in the general population.2022Journal of hepatology
Trials on ClinicalTrials.gov6
  1. Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted TherapyNot yet recruitingNCT07537777Lead sponsorPhase 2Start 2026-04
  2. Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and ImmunotherapyNot yet recruitingNCT07565415Lead sponsorPhase 2Start 2026-06
  3. QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTTRecruitingNCT07327788Lead sponsorPhase 2Start 2025-12
  4. Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort StudyRecruitingNCT06861114Lead sponsorStart 2025-02
  5. Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and ImmunotherapyRecruitingNCT07436845Lead sponsorStart 2025-12
  6. Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCSNot yet recruitingNCT06317896Lead sponsorStart 2024-04

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.7%Leads about 1 in 60 of China's research papers on Stomach cancer

Led 162 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
12
Research papers it led
162
Trials it led
31
Share of China's trials
2.1%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsImaging & AI

Hospitals counted here

  1. Nanfang Hospital127
  2. Zhujiang Hospital10
  3. Shenzhen Hospital, Southern Medical University Counted in the group total5
  4. Shunde Hospital of Southern Medical University Counted in the group total3
  5. Affiliated Dongguan Shilong People's Hospital of Southern Medical University2
  6. Affiliated Hexian Memorial Hospital of Southern Medical University Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Joint Nasogastric Tube Versus Traditional Decompression Nasogastric Tube to Guided OGT-Overlap Esophagojejunostomy in Laparoscopic Total Gastrectomy: A Randomized Controlled Trial.2025Annals of surgical oncologyRCT
  2. Effect of Perioperative Interleukin-6 and Tumor Necrosis Factor-α on Long-Term Outcomes in Locally Advanced Gastric Cancer: Results from the CLASS-01 Trial.2022Journal of immunology researchRCTFree full text
  3. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer.2024Journal for immunotherapy of cancerFree full text
  4. Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study.2023Journal for immunotherapy of cancerFree full text
  5. Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer-Reply.2022JAMA surgery
Trials on ClinicalTrials.gov6
  1. Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric CancerNot yet recruitingNCT07511894Lead sponsorPhase 2Start 2026-05
  2. Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07603349Lead sponsorPhase 2/Phase 3Start 2026-06
  3. An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric AdenocarcinomaEnrolling by invitationNCT07274579Lead sponsorStart 2025-10
  4. Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric CancerRecruitingNCT07294638Lead sponsorStart 2025-07
  5. A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningRecruitingNCT07032961Lead sponsorStart 2025-06
  6. Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric TissueNot yet recruitingNCT07276854Lead sponsorStart 2025-12

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
1.0%Leads about 1 in 100 of China's research papers on Retinoblastoma

Led 3 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Shenzhen Eye Hospital1
  2. Zhujiang Hospital1
  3. Shenzhen Hospital, Southern Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
1.9%Leads about 1 in 53 of China's research papers on Chordoma New since 2021

Led 2 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Dongguan People's Hospital1
  2. Zhujiang Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.5%Leads about 1 in 66 of China's research papers on Osteosarcoma

Led 34 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
34
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Zhujiang Hospital9
  2. Third Affiliated Hospital of Southern Medical University9
  3. Nanfang Hospital6
  4. Affiliated Hospital of Southern Medical University2
  5. Maoming People's Hospital1
  6. Southern Medical University Pingshan Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.4%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour ▼ from 3.7%

Led 2 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
2
Share of China's trials
2.7%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Nanfang Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.7%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 8 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
1
Share of China's trials
2.4%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Zhujiang Hospital6
  2. Nanfang Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.6%Leads under 1 in 100 of China's research papers on Myeloma

Led 10 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
4
Research papers it led
10
Trials it led
7
Share of China's trials
1.4%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesDiagnosis, MRD & riskRelapse & resistanceStem cell transplant

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Nanfang Hospital3
  2. Third Affiliated Hospital of Southern Medical University3
  3. Zhujiang Hospital2
  4. Huadu District People's Hospital Counted in the group total1
  5. Eighth Affiliated Hospital of Southern Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Low peripheral blood B lymphocyte count predicts poor outcome in patients with multiple myeloma.2025Immunobiology
  2. Prognostic value assessment and in vitro validation of mitochondria-ferroptosis-related genes in multiple myeloma.2025Scientific reportsFree full text
  3. Single-cell profiling uncovers PTPRG-driven stemness in malignant plasma cells and signatures of treatment failure in multiple myeloma.2025Frontiers in immunologyFree full text
  4. Overexpression of Pin1 regulated by TOP2A, which subsequently stabilizes Pyk2 to promote bortezomib resistance in multiple myeloma.2025Cancer gene therapy
  5. Targeting PARP14 with lomitapide suppresses drug resistance through the activation of DRP1-induced mitophagy in multiple myeloma.2024Cancer letters
Trials on ClinicalTrials.gov6
  1. Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic MalignanciesRecruitingNCT06758713Lead sponsorPhase 1Start 2025-01
  2. Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal GammopathyRecruitingNCT06690593Lead sponsorStart 2024-12
  3. Intestinal Flora and Immunity in Monoclonal Gammopathy PatientsRecruitingNCT06539832Lead sponsorStart 2024-05
  4. Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS AnalysisRecruitingNCT05686447Lead sponsorStart 2023-01
  5. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  6. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
4.0%Leads about 1 in 25 of China's research papers on B-ALL New since 2021

Led 9 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
2
Research papers it led
9
Trials it led
6
Share of China's trials
2.4%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 222025
ThemesPhiladelphia chromosome & geneticsMRD & relapseChildren

Hospitals counted here

  1. Nanfang Hospital8
  2. Zhujiang Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Refining Risk Stratification for B-cell Precursor Adult Acute Lymphoblastic Leukemia Treated With a Pediatric-inspired Regimen by Combining IKZF1 Deletion and Minimal Residual Disease.2025Transplantation and cellular therapy
  2. STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.2024British journal of haematology
  3. PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.2024British journal of haematology
  4. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.2022Hematology (Amsterdam, Netherlands)
  5. Integrating bulk RNA-seq and scRNA-seq data to explore diverse cell death patterns and develop a programmed cell death-related relapse prediction model in pediatric B-ALL.2025Scientific reportsFree full text
Trials on ClinicalTrials.gov6
  1. Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute LeukemiaNot yet recruitingNCT07696481Lead sponsorEarly phase 1Start 2026-08
  2. CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical StudyRecruitingNCT07072494Lead sponsorPhase 1/Phase 2Start 2025-07
  3. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  4. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  5. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  6. Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic LeukemiaRecruitingNCT06450067Study siteStart 2024-06

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.5%Leads under 1 in 100 of China's research papers on Aplastic anaemia

Led 2 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025
ThemesStem cell transplantChildren

Hospitals counted here

  1. Dongguan People's Hospital Counted in the group total1
  2. Nanfang Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
1.0%Leads about 1 in 100 of China's research papers on HLH

Led 4 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 112025
ThemesTreatment regimensChildrenEBV & infection triggers

Hospitals counted here

  1. Zhujiang Hospital Counted in the group total1
  2. Nanfang Hospital Counted in the group total1
  3. Shenzhen Hospital, Southern Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
9.9%Leads about 1 in 10 of China's research papers on Beta thalassaemia ▲ from 6.1%

Led 31 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
31
Trials it led
5
Share of China's trials
10.6%
Share of the world's papers
1.8%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025

Hospitals counted here

  1. Nanfang Hospital21
  2. Child Healthcare Hospital2
  3. Child Health Care Hospital1
  4. Zhujiang Hospital1
  5. Dongguan People's Hospital1
  6. Zhongshan Boai Hospital, Southern Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Target-allele-specific probe single-base extension (TASP-SBE): a novel MALDI-TOF-MS strategy for multi-variants analysis and its application in simultaneous detection of α-/β-thalassemia mutations.2023Human geneticsRCT
  2. Identification of a Patient with Transfusion-Dependent β-Thalassemia Caused by Compound Heterozygous Mutations of HBB: C.84_85insC and Common Linked Intronic Variants in HBB.2025Hemoglobin
  3. Clinical evaluation of target capture sequencing technique for noninvasive prenatal diagnosis of β-thalassemia: A prospective case series.2025Medicine
  4. A Chinese pediatric patient with thalassemia traits and compound heterozygous mutations in the PIEZO1 gene suspected of having dehydrated hereditary stomatocytosis.2025Hematology (Amsterdam, Netherlands)
  5. Whole-genome Sequencing Association Analysis of Quantitative Platelet Traits in A Large Cohort of β-thalassemia.2025Genomics, proteomics & bioinformatics
Trials on ClinicalTrials.gov6
  1. Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingNCT04143724Study sitePhase 2Start 2019-11
  2. Evaluation of Heart Status in Patients of Beta Thalassemia Using EchocardiogramStatus unknownNCT04929574Lead sponsorStart 2021-07
  3. Association of Hb F Level With Clinical Severity of Beta ThalassemiaStatus unknownNCT04917978Lead sponsorStart 2019-12
  4. Genetic Variants Affecting the Clinical Severity of Beta ThalassemiaStatus unknownNCT04918056Lead sponsorStart 2017-01
  5. Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically ModifiedStatus unknownNCT03276455Lead sponsorPhase 1/Phase 2Start 2017-09
  6. Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia MajorStatus unknownNCT02126046Lead sponsorN/AStart 2012-09

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
3.3%Leads about 1 in 30 of China's research papers on Haemophilia A ▼ from 5.4%

Led 9 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. Nanfang Hospital9
  2. Seventh Affiliated Hospital of Southern Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Coagulation Factor Consumption and Medium- to Long-Term Outcomes of Achilles Tendon Lengthening With and Without External Fixation in Haemophilia.2026Haemophilia : the official journal of the World Federation of Hemophilia
  2. Treatment of fracture in haemophilia: a retrospective study.2026International orthopaedics
  3. Efficacy and Safety of Recombinant Factor VIII in Previously Untreated and Previously Treated Children with Hemophilia A: A Systematic Review.2025Advances in therapy
  4. Surgical treatment for patients with hemophilic pseudotumor-related femoral fracture: a retrospective study.2021Journal of orthopaedic surgery and research
  5. Application of capillary gel electrophoresis in detection of Factor VIII gene intron 22 inversion of hemophilia A.2025Journal of hematopathology
Trials on ClinicalTrials.gov6
  1. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia ARecruitingNCT07416604Study sitePhase 3Start 2026-04
  2. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  3. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Study sitePhase 3Start 2022-12
  4. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Study sitePhase 3Start 2021-11
  5. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ANot yet recruitingNCT06136507Study sitePhase 3Start 2026-12
  6. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
1.0%Leads about 1 in 97 of China's research papers on NMOSD

Led 5 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 112025
ThemesAntibodies & diagnosis

Hospitals counted here

  1. Nanfang Hospital3
  2. Zhujiang Hospital Counted in the group total1
  3. Shenzhen Hospital, Southern Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.2%Leads under 1 in 100 of China's research papers on Myasthenia gravis

Led 1 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.04%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025
ThemesThymus & thymectomy

Hospitals counted here

  1. Nanfang Hospital1
  2. Dongguan People's Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
2.0%Leads about 1 in 51 of China's research papers on Moyamoya ▲ from 0.4%

Led 7 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 112025
ThemesRevascularisation surgeryImaging & blood flowGenetics

Hospitals counted here

  1. Nanfang Hospital6
  2. Zhujiang Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
2.6%Leads about 1 in 38 of China's research papers on Anti-NMDA receptor encephalitis ▼ from 8.9%

Led 7 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Nanfang Hospital7

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.7%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 7 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Nanfang Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Bioinformatics-based identification of mirdametinib as a potential therapeutic target for idiopathic pulmonary fibrosis associated with endoplasmic reticulum stress.2025Naunyn-Schmiedeberg's archives of pharmacology
  2. Tetrandrine alleviates pulmonary fibrosis by inhibiting alveolar epithelial cell senescence through PINK1/Parkin-mediated mitophagy.2024European journal of pharmacology
  3. Amygdalin epimers exert discrepant anti-pulmonary fibrosis activity via inhibiting TGF-β1/Smad2/3 pathway.2023Pulmonary pharmacology & therapeutics
  4. RNF130 protects against pulmonary fibrosis through suppressing aerobic glycolysis by mediating c-myc ubiquitination.2023International immunopharmacology
  5. Extracellular HSP90α promotes cellular senescence by modulating TGF-β signaling in pulmonary fibrosis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Trials on ClinicalTrials.gov5
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  3. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  4. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  5. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
1.7%Leads about 1 in 60 of China's research papers on Amyotrophic lateral sclerosis ▲ from 0.5%

Led 13 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Nanfang Hospital6
  2. Shenzhen Hospital, Southern Medical University2
  3. Fifth Affiliated Hospital of Southern Medical University1
  4. Zhujiang Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
2.7%Leads about 1 in 36 of China's research papers on Fabry disease New since 2021

Led 2 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Nanfang Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
0.8%Leads under 1 in 100 of China's research papers on Behçet disease New since 2021

Led 2 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. Stomatological Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.9%Leads under 1 in 100 of China's research papers on IgA nephropathy

Led 7 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
1
Research papers it led
7
Trials it led
2
Share of China's trials
1.7%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 222025

Hospitals counted here

  1. Nanfang Hospital5
  2. Zhujiang Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.2023JAMA network openRCT
  2. Association of urinary LIF levels with disease prognosis and treatment response to methylprednisolone in IgA nephropathy.2025Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  3. Intensity of Macrophage Infiltration in Glomeruli Predicts Response to Immunosuppressive Therapy in Patients with IgA Nephropathy.2021Journal of the American Society of Nephrology : JASN
  4. Investigating the genetic effects of metformin-related targets on IgA nephropathy using Mendelian randomization.2025Renal failure
  5. Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting.2023Clinical journal of the American Society of Nephrology : CJASN
Trials on ClinicalTrials.gov6
  1. Efficacy and Safety of Nefecon on Prevention of Relapse of IgA NephropathyRecruitingNCT07604311Lead sponsorPhase 4Start 2026-06
  2. Correlation of Microbiome and Metabonomics With IgA NephropathyRecruitingNCT05190848Study siteStart 2020-05
  3. The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy PatientsCompletedNCT01854814Lead sponsorN/AStart 2013-07
  4. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  5. A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.CompletedNCT05016323Study sitePhase 2Start 2021-09
  6. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.7%Leads under 1 in 100 of China's research papers on Primary biliary cholangitis

Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Nanfang Hospital1
  2. Shenzhen Hospital, Southern Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Congenital diaphragmatic hernia

先天性膈疝
3.3%Leads about 1 in 30 of China's research papers on Congenital diaphragmatic hernia

Led 2 of 60 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (18.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Nanfang Hospital1
  2. Affiliated Hexian Memorial Hospital of Southern Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
3.1%Leads about 1 in 32 of China's research papers on Hirschsprung disease ▲ from 0.7%

Led 5 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 2220242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Zhujiang Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
3.4%Leads about 1 in 29 of China's research papers on Familial adenomatous polyposis New since 2021

Led 2 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Nanfang Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov